UK markets close in 2 hours 34 minutes

CureVac N.V. (CVAC)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
57.85+2.55 (+4.61%)
At close: 4:00PM EDT
56.75 -1.10 (-1.90%)
Pre-market: 08:51AM EDT
Sign in to post a message.
  • E
    Eye
    The European Medicines Agency ("EMA") said that it likely won't be until the end of the year that it will be in a position to determine the "next step" for CureVac's (CVAC +2.8%) COVID-19 vaccine.

    During a press briefing today, Marco Cavaleri, EMA's head of biological health threats and vaccines strategy, said the company has filed data that is "quite important for us as a starting point to see where we are with this application," adding he expects that the agency will be in a better position by year end to determine the next step for the vaccine.

    Seeking Alpha contributor Chetan Woodun, who has a neutral rating on CureVac shares, says that investors should wait for concrete news about the company before investing.
  • G
    Gino
    It's worth reading the cancellation release carefully. The reassessment for short-term demand is expected and on that basis alone shouldn't be a reason to be bearish. But there is also the kicker in the last sentence "The parties agreed not to disclose financial details of the cancellation". Ie maybe CVAC has had to pay to come out of the agreement, so a future loss on the horizon. Ouch. We'll find out when Q3 financials have been released. Having said that these are short-term concerns only, technology and longer term prospects are unchanged.
  • N
    Nathan
    Curevac cancelled contracts only with 2 companies and only due to demand. With other companies curevac is moving forward. Do not sell, curevac will have approval.
  • J
    Jason
    This month or october beginning first gen vaccine will be approved!!!
  • E
    Eye
    Curevac files for up to $600M mixed shelf registration…
  • L
    Logan
    Back to 75$
  • a
    aircat
    CureVac Announces Contracts With WACKER And Celonic Terminated, Rentschler Biopharma And Novartis Unaffected; Says 'The decision was made in response to the reduced short-term peak demand for vaccines'
    Still waiting for EMA.
  • a
    again
    $NVAX conversation
    A 40-year-old who collapsed and died at the entrance to a studio room was vaccinated with Moderna two days ago Input 2021.09.15. Edited at 5:18 PM, 2021.09.15. 5:19 PM Reporter Im Hyun-jung Angry Sad Sad Like Rate 1,063 254 Using a text-to-speech service Change the font size Send SNS view original Moderna Vaccine / AFP=News1 In Andong, North Gyeongsang Province, a 40-year-old who was vaccinated with Moderna died, and quarantine authorities launched an epidemiological investigation. According to the Newsis report, a resident found A (in her 40s) lying in front of the entrance to a studio in Pyeonghwa#$%$ Andong-si around 8 am on the 15th, and called 911. The 119 rescue team moved A, who showed symptoms of breathing difficulties, to a nearby hospital, but eventually died. It is known that he received the Moderna 1st vaccine on the 13th. The quarantine authorities are investigating to determine whether the death of Mr. A is related to vaccination. Police are expected to conduct an autopsy on the 16th to investigate the exact cause of death. Reporter Im Hyun-jung $mrna $pfe $bntx $cvac
  • E
    Eduardo
    EMA will review Curevac clinical data in the coming weeks (see below link - 26:40).

    https://www.youtube.com/watch?v=RonCekqjXIg
    EMA press briefing 9 September 2021
    www.youtube.com
  • N
    Nathan
    Curevac stock is a great opportunity. This month it will be granted ema authorization. With the lawest dose, the cheapest vaccine will be sold immediately!
  • b
    bob
    Back to $65 again and potentially buyout???
  • J
    Jason
    Curevac the best opportunity now! ROCKET
  • m
    michelle
    For all who haven't heard, cvac cancelled 2 contracts; hence the price drop.
  • J
    Jason
    Wacker and Celonic does NOT matter! Its only due to demand. First gen vaccine will be approved anyway. No need to worry!
  • A
    Aad
    No worries about these short term hickups. 2nd gen will be better and should generate income. If you’re invested in this company you shouldn’t have done it only as a Covid play anyway. This is a longterm hold.
  • D
    Db7
    Old news! Another great way for the powers above to bring down the value😳
  • M
    Mason
    This stock is a great opportunity. It was wrongly evaluated with first gen vaccine. Now first gen vaccine is going to be approved soon. Ceo of curevac Haas during last curevac video said that the vaccine will be approved for sure. Other collaborating companies are preparing for production. Soon stock will be back 150$
  • R
    Ray
    CureVac N.V. (CVAC) - FORM F-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers
  • g
    gg
    What is the meaning of a cancellation? Why do they need to cancel at this time before even getting the approval for their vaccine? Here are the probable reasons.

    1) They had a deadline to start the manufacturing, as the vaccine is not approved, they have to pay compensation for the period when they do not start manufacturing. Better to stop cost.

    2) Why they did not cancel the other contracts? Probably those contracts do not have a strict clause on when to start the production.

    I think if we ignore these manufacturing contracts, what is the probability that their vaccine will be approved? Any timelines to get it approved?
  • E
    Eye
    EMA unlikely to make a decision on CureVac COVID vaccine until at least year end